Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037183 | 0.93 | NPC1 (0.45) | PPARAPPARDGAASMN1; SMN2RAB9A | |
| SCHEMBL5032944 | 0.92 | PPARA (0.56) | PPARAPPARDGAASMN1; SMN2CHRM4 | |
| SCHEMBL5034446 | 0.91 | SCD (0.41) | PPARAPPARDCHRM4KDM4EPPARG | |
| SCHEMBL5034527 | 0.86 | PPARA (0.47) | PPARAPPARDGAASMN1; SMN2CHRM4 | |
| SCHEMBL5034516 | 0.85 | PPARA (0.46) | PPARAPPARDGAASMN1; SMN2CHRM4 | |
| SCHEMBL5037056 | 0.85 | PPARG (0.42) | PPARANPC1PPARGHPGD | |
| SCHEMBL5032938 | 0.82 | PPARA (0.49) | PPARAPPARDGAASMN1; SMN2CHRM4 | |
| SCHEMBL5034523 | 0.80 | HPGD (0.46) | PPARAGAASMN1; SMN2NPC1PPARG | |
| SCHEMBL5031926 | 0.79 | PPARA (0.44) | PPARAPPARDGAARAB9ANPC1 | |
| SCHEMBL6427465 | 0.78 | PPARA (0.39) | PPARAPPARDKDM4EPPARGHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | PPARA 1/4885PPARD 3/4885GAA 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.